17.15
-0.06%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sinopharm Group Co
Its shares trade on HKEX under the ticker 1099.HK. It has been listed since 23 September 2009. In the fiscal year to 31 December 2025, it reported revenue of CN¥669.46bn and net income of CN¥8.33bn. At that date it held total assets of CN¥454.55bn and shareholders' equity of CN¥97.76bn.
Sinopharm Group Co., Ltd. is a distributor of pharmaceutical and healthcare products and a value added supply chain service provider in the People's Republic of China. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2009-09-23. The firm operates through three business segments. The Pharmaceutical Distribution segment is engaged in the distribution of medicines, medicine devices and pharmaceutical products to hospitals, other distributors, retail drug stores and clinics. The Retail Pharmacy segment is engaged in the operation of medicine chain stores. The Other Business segment is engaged in the distribution of laboratory supplies, the manufacture and distribution of chemical reagents, as well as the production and sales of pharmaceutical products. The firm is also engaged in the provision of pharmaceutical logistics services and property rental business in China through its subsidiaries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 23 Sept 2009
- Employees
- 93,764
- Website
- sinopharmgroup.com.cn ↗
Leadership
Pay as last reported
- Mr. Wanyong LianPresident, Executive Director, since 2008
- Mr. Qiyu ChenNon-Executive Vice Chairman of the Board
- Ms. Xiaojuan LiChief Financial Officer
- Mr. Maisong CaiVice President, since 2022
- Mr. Zhanyu ChenVice President
- Mr. Xiuchang JiangVice President
- Mr. Yang LiVice President
- Mr. Yijian WuCompany Secretary, since 2016
- Ms. Rongli FengNon-Executive Director
- Mr. Dongjiu LiNon-Executive Director, since 2013
- Mr. Deyong WenNon-Executive Director
- Mr. Bingxiang ZhaoNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 63
- Environment
- 83
- Social
- 78
- Governance
- 28
- Direct emissions (scope 1)
- 48,785.71 t
- Energy emissions (scope 2)
- 177,259.36 t
- Value chain emissions (scope 3)
- 318,336.83 t
- Women in the workforce
- 61.87845%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sinopharm Group Co Ltd has a strong market position in the pharmaceutical industry, being one of the largest companies in China.
- The company benefits from a diversified product portfolio, including prescription drugs, over-the-counter medicines, vaccines, and healthcare services.
- Sinopharm has an extensive distribution network and strong relationships with hospitals and healthcare institutions across the country.
Weaknesses
- The company may face challenges in expanding its international presence and competing with well-established multinational pharmaceutical companies.
- Sinopharm Group Co Ltd heavily relies on government regulations and policies, which can impact its operations and profitability.
- There may be limitations in the company's research and development capabilities compared to some global pharmaceutical giants.
Opportunities
- Sinopharm can capitalize on the growing demand for healthcare services in China's aging population and the increasing prevalence of chronic diseases.
- The company can further expand its product portfolio by focusing on innovative healthcare solutions, such as biotechnology and personalized medicine.
- Sinopharm has the opportunity to expand its presence in emerging markets with less competition and increasing healthcare spending.
Threats
- Sinopharm Group Co Ltd faces the risk of increased competition from both domestic and international pharmaceutical companies in the Chinese market.
- The company may be exposed to uncertainties related to healthcare regulations and policies, which can impact its business operations.
- Sinopharm may face reputational risks due to potential product recalls or safety issues, which can affect consumer trust and market reputation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.